For patients starting from a higher genetic-risk baseline (e.g., post chemo/TBI), does embryo screening yield higher marginal benefit due to increased variance between embryos, or does elevated de novo mutation noise reduce effective selection signal?
For patients starting from a higher genetic-risk baseline (e.g., post chemo/TBI), does embryo screening yield higher marginal benefit due to increased variance between embryos, or does elevated de novo mutation noise reduce effective selection signal?